— WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events — […]
— First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with
— Veteran biopharmaceutical executive Mark Alles brings more than three decades of global hematology and oncology experience, and significant corporate
— Cytokine-induced memory-like (CIML) NK cells engaged and activated endogenous adaptive immunity in the tumor microenvironment (TME) — -WU-NK-101 demonstrated
— Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance —
— Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer — ST. LOUIS, MO and SAN DIEGO, CA, March
— WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors — –WU-NK-101 exhibited robust trafficking, intra-tumor infiltration,
— Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell
SAINT LOUIS, MO and SAN DIEGO, CA, November 10, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline
— WU-NK-101’s differentiated memory natural killer (NK) expression profile supports enhanced anti-tumor activity and metabolic flexibility — — Data support